Could a fungal drug stop esophageal cancer before it starts?
NCT ID NCT06732388
First seen Jan 22, 2026 · Last updated Jun 15, 2026 · Updated 30 times
Summary
This study tests whether adding the antifungal drug itraconazole to standard ablation therapy can prevent esophageal cancer in people with high-risk Barrett's esophagus. About 64 participants will receive either itraconazole or a placebo alongside their usual endoscopic ablation. The goal is to see if the drug helps eliminate precancerous tissue faster and reduces the chance of cancer developing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor University Medical Center
Dallas, Texas, 75246, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Case Western Reserve University
Cleveland, Ohio, 44106, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27599, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Kansas Cancer Center
Kansas City, Kansas, 66160, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.